Labcorp (NYSE:LH) Director Sells $954,060.00 in Stock

Labcorp Holdings Inc. (NYSE:LH) Director Kerrii Anderson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the sale, the director owned 6,563 shares in the company, valued at approximately $2,087,165.26. This represents a 31.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Price Performance

NYSE:LH opened at $332.67 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $291.11 and a 200 day simple moving average of $276.34. Labcorp Holdings Inc. has a 1-year low of $244.52 and a 1-year high of $338.19. The stock has a market capitalization of $26.98 billion, a PE ratio of 27.52, a P/E/G ratio of 1.91 and a beta of 0.87.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same quarter last year, the company posted $4.35 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts expect that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is presently 23.82%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LH. JPL Wealth Management LLC acquired a new position in shares of Labcorp in the third quarter valued at about $28,000. Hilton Head Capital Partners LLC acquired a new stake in Labcorp in the 4th quarter worth about $27,000. DV Equities LLC bought a new stake in Labcorp in the 4th quarter valued at about $29,000. Allied Private Wealth LLC bought a new stake in Labcorp in the 2nd quarter valued at about $33,000. Finally, Headlands Technologies LLC grew its position in shares of Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on LH. Truist Financial upped their price objective on Labcorp from $320.00 to $350.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Barclays boosted their target price on Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $306.00 price target on shares of Labcorp in a research note on Friday, July 31st. Robert W. Baird set a $352.00 price target on Labcorp in a report on Friday, July 31st. Finally, Bank of America lifted their price objective on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $330.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.